Weight loss products maker Medifast Q3 revenue declines amid challenges in client acquisition

Reuters

Nov 04

Weight loss products maker Medifast Q3 revenue declines amid challenges in client acquisition

Overview

Medifast Q3 revenue falls 36.2% yr/yr due to fewer active earning coaches
Company reports Q3 net loss of $2.3 mln, compared to net income last year
Medifast maintains strong balance sheet with $173.5 mln in cash, no debt

Outlook

Company expects Q4 2025 revenue between $65 mln and $80 mln
Company projects Q4 2025 diluted loss per share between $0.70 and $1.25

Result Drivers

COACH DECLINE - Revenue decrease primarily driven by 35% drop in active earning OPTAVIA coaches
GLP-1 IMPACT - Challenges in client acquisition due to acceptance of GLP-1 medications for weight loss
STRATEGIC TRANSFORMATION - Co is shifting focus to metabolic health, aiming for larger market

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Revenue		$89.40 mln
Q3 EPS		-$0.21
Q3 Net Income		-$2.26 mln

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the food processing peer group is "buy."
Wall Street's median 12-month price target for Medifast Inc is $15.00, about 19.9% above its October 31 closing price of $12.02

Press Release: ID:nBw4xsXfHa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2580922328"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580922328\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580922328?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 05:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580922328","market":"us","top_or_hot":-1,"title":"Weight loss products maker Medifast Q3 revenue declines amid challenges in client acquisition","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Weight loss products maker Medifast Q3 revenue declines amid challenges in client acquisition</title></head><body><p><span>Overview</span></p><ul><li><p>Medifast Q3 revenue falls 36.2% yr/yr due to fewer active earning coaches</p></li><li><p>Company reports Q3 net loss of $2.3 mln, compared to net income last year</p></li><li><p>Medifast maintains strong balance sheet with $173.5 mln in cash, no debt</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects Q4 2025 revenue between $65 mln and $80 mln</p></li><li><p>Company projects Q4 2025 diluted loss per share between $0.70 and $1.25</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>COACH DECLINE - Revenue decrease primarily driven by 35% drop in active earning OPTAVIA coaches</p></li><li><p>GLP-1 IMPACT - Challenges in client acquisition due to acceptance of GLP-1 medications for weight loss</p></li><li><p>STRATEGIC TRANSFORMATION - Co is shifting focus to metabolic health, aiming for larger market</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td></td><td><p>$89.40 mln</p></td><td></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.21</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$2.26 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the food processing peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Medifast Inc is $15.00, about 19.9% above its October 31 closing price of $12.02</p></li></ul><p>Press Release: <span>ID:nBw4xsXfHa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Weight loss products maker Medifast Q3 revenue declines amid challenges in client acquisition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWeight loss products maker Medifast Q3 revenue declines amid challenges in client acquisition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-04 05:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Weight loss products maker Medifast Q3 revenue declines amid challenges in client acquisition</title></head><body><p><span>Overview</span></p><ul><li><p>Medifast Q3 revenue falls 36.2% yr/yr due to fewer active earning coaches</p></li><li><p>Company reports Q3 net loss of $2.3 mln, compared to net income last year</p></li><li><p>Medifast maintains strong balance sheet with $173.5 mln in cash, no debt</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects Q4 2025 revenue between $65 mln and $80 mln</p></li><li><p>Company projects Q4 2025 diluted loss per share between $0.70 and $1.25</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>COACH DECLINE - Revenue decrease primarily driven by 35% drop in active earning OPTAVIA coaches</p></li><li><p>GLP-1 IMPACT - Challenges in client acquisition due to acceptance of GLP-1 medications for weight loss</p></li><li><p>STRATEGIC TRANSFORMATION - Co is shifting focus to metabolic health, aiming for larger market</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td></td><td><p>$89.40 mln</p></td><td></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.21</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$2.26 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the food processing peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Medifast Inc is $15.00, about 19.9% above its October 31 closing price of $12.02</p></li></ul><p>Press Release: <span>ID:nBw4xsXfHa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nL1N3WF10J:1","article_id":"2580922328","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580922328","pubTimestamp":1762204818,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Weight loss products maker Medifast Q3 revenue declines amid challenges in client acquisitionOverviewMedifast Q3 revenue falls 36.2% yr/yr due to fewer active earning coachesCompany reports Q3 net los","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4532":"文艺复兴科技持仓","MED":"快验保","BK4183":"个人用品"},"translate_title":"减肥产品制造商快验保第三季度收入因客户获取挑战而下降","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MED":0.9},"content_text":"Weight loss products maker Medifast Q3 revenue declines amid challenges in client acquisitionOverviewMedifast Q3 revenue falls 36.2% yr/yr due to fewer active earning coachesCompany reports Q3 net loss of $2.3 mln, compared to net income last yearMedifast maintains strong balance sheet with $173.5 mln in cash, no debtOutlookCompany expects Q4 2025 revenue between $65 mln and $80 mlnCompany projects Q4 2025 diluted loss per share between $0.70 and $1.25Result DriversCOACH DECLINE - Revenue decrease primarily driven by 35% drop in active earning OPTAVIA coachesGLP-1 IMPACT - Challenges in client acquisition due to acceptance of GLP-1 medications for weight lossSTRATEGIC TRANSFORMATION - Co is shifting focus to metabolic health, aiming for larger marketKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Revenue$89.40 mlnQ3 EPS-$0.21Q3 Net Income-$2.26 mlnAnalyst CoverageThe current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the food processing peer group is \"buy.\"Wall Street's median 12-month price target for Medifast Inc is $15.00, about 19.9% above its October 31 closing price of $12.02Press Release: ID:nBw4xsXfHaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"merge","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}